Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47%Simplywall·Aug 12 at 11:41 AMVYGR-0.58%
Voyager Therap | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 3.165 MEarnings Watch·Aug 7 at 03:14 AMVYGR-0.58%
Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on WednesdayMarket Beat·Jul 29 at 11:56 AMVYGR-0.58%
Voyager Therapeutics advances tau-silencing gene therapy programTip Ranks·Jul 13 at 05:27 PMVYGR-0.58%
Voyager Therapeutics reports favorable GLP tox and durable CNS tau lowering for VY1706 ahead of clinical dosingTradingView·Jul 13 at 12:53 PMVYGR-0.58%
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 | VYGR Stock NewsStockTitan·Jul 13 at 04:01 AMVYGR-0.58%
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top AnalystTip Ranks·Jul 6 at 10:35 AMVYGR-0.58%
Jim Cramer: TE Connectivity Is ‘Terrific,’ Buy This Industrial Stockbenzinga_article·Jul 1 at 11:49 AMGEV0.00%VYGR-0.58%
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 | VYGR Stock NewsStockTitan·Jun 29 at 04:01 AMVYGR-0.58%
